AAAAAA
Results:
1-11
|
Results: 11
Authors:
Harrison, TW
Citation: Tw. Harrison, Systemic availability of inhaled budesonide and fluticasone propionate - Healthy versus asthmatic lungs, BIODRUGS, 15(6), 2001, pp. 405-411
Authors:
Tattersfield, AE
Harrison, TW
Citation: Ae. Tattersfield et Tw. Harrison, Exacerbations of asthma - still room for improvement, LANCET, 358(9282), 2001, pp. 599-601
Authors:
Harrison, TW
Wisniewski, A
Honour, J
Tattersfield, AE
Citation: Tw. Harrison et al., Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects, THORAX, 56(3), 2001, pp. 186-191
Authors:
Tattersfield, AE
Harrison, TW
Citation: Ae. Tattersfield et Tw. Harrison, Inhaled steroids for COPD?, THORAX, 56, 2001, pp. 2-6
Authors:
Bennett, JA
Harrison, TW
Tattersfield, AE
Citation: Ja. Bennett et al., The contribution of the swallowed fraction of an inhaled dose of salmeterol to it systemic effects, EUR RESP J, 13(2), 1999, pp. 445-448
Authors:
Tattersfield, AE
Harrison, TW
Citation: Ae. Tattersfield et Tw. Harrison, Step 3 of the asthma guidelines, THORAX, 54(9), 1999, pp. 753-754
Authors:
Harrison, TW
Citation: Tw. Harrison, Beta agonist dose reduction in asthma - Reply, THORAX, 54(9), 1999, pp. 861-861
Authors:
Harrison, TW
Oborne, J
Wilding, PJ
Tattersfield, AE
Citation: Tw. Harrison et al., Randomised placebo controlled trial of beta agonist dose reduction in asthma, THORAX, 54(2), 1999, pp. 98-102
Authors:
Phillips, K
Harrison, TW
Tattersfield, A
Citation: K. Phillips et al., New drugs in asthma, J ROY COL P, 33(5), 1999, pp. 425-430
Authors:
Harrison, TW
Citation: Tw. Harrison, Herodotus, CLASS REV, 49(2), 1999, pp. 364-366
Authors:
Harrison, TW
Tattersfield, AE
Citation: Tw. Harrison et Ae. Tattersfield, Effect of single doses of inhaled lignocaine on FEV1 and bronchial reactivity in asthma, RESP MED, 92(12), 1998, pp. 1359-1363
Risultati:
1-11
|